Stoke filed a $200,000,000 at-the-market supplement with Cantor Fitzgerald & Co. as sales agent, which can be paid up to 3.0% of gross proceeds. It replaces an earlier supplement under which the company sold about 4.7 million shares for net proceeds of $146.4 million.
Stoke's shelf includes a $150,000,000 at-the-market program with Cantor Fitzgerald, which can be paid up to 3.0% of gross proceeds in commissions. The stock's last reported sale price was $33.96 on March 16, 2026.
Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $110.0 million, plus short-term investments of $182.8 million, $292.8 million in all.
Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice.
Questions about Stoke Therapeutics
Has Stoke Therapeutics raised money recently?
Our latest story on this, dated Aug 3, 2026: "Stoke Therapeutics files new $200,000,000 at-the-market stock program". The story links the filing or release it is based on. Read the story.
What is the ticker symbol of Stoke Therapeutics?
Stoke Therapeutics, Inc. trades under the ticker STOK on NASDAQ.
Where is Stoke Therapeutics listed?
Stoke Therapeutics, Inc. is listed on NASDAQ. Our directory also records these other listings: GETTEX:0GT; LS:A2PLTL; LSX:A2PLTL.
What is the SEC CIK of Stoke Therapeutics?
The SEC Central Index Key (CIK) for Stoke Therapeutics, Inc. is 1623526. Its filings are on SEC EDGAR.
How many shares does Stoke Therapeutics have outstanding?
64,526,242 shares as of 2026-07-30, per the cover page of its 10-Q filed 2026-08-03.
Which country or territory is Stoke Therapeutics listed under?
Our directory records Stoke Therapeutics, Inc. under United States.
What does Stoke Therapeutics do?
Our directory classifies Stoke Therapeutics, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.
What is the ISIN of Stoke Therapeutics?
The ISIN recorded for Stoke Therapeutics, Inc. is US86150R1077.
Does aibio.space cover Stoke Therapeutics?
aibio.space lists Stoke Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
Where is Stoke Therapeutics incorporated?
SEC records list its state or country of incorporation as DE.
What was Stoke Therapeutics's revenue last year?
$184.4 million for the fiscal year ended Dec 31, 2025, as reported to the SEC.
Is Stoke Therapeutics profitable?
Stoke Therapeutics, Inc. reported a net loss of $6.9 million for the fiscal year ended Dec 31, 2025, and generated $45.6 million of cash from operations, per its annual report to the SEC.
How much does Stoke Therapeutics spend on research and development?
$137.9 million in the fiscal year ended Dec 31, 2025, per its annual report.
How much cash does Stoke Therapeutics have?
$292.8 million in cash and short-term investments at Jun 30, 2026, per its 10-Q.
What is the latest Stoke Therapeutics (STOK) stock news?
Our latest story on Stoke Therapeutics, dated Aug 3, 2026: "Stoke Therapeutics files new $200,000,000 at-the-market stock program". Stoke filed a $200,000,000 at-the-market supplement with Cantor Fitzgerald & Co. as sales agent, which can be paid up to 3.0% of gross proceeds. It replaces an earlier supplement under which the company sold about 4.7 million shares for net proceeds of $146.4 million. Source.
Investor discussion: Stoke Therapeutics
Members talk about Stoke Therapeutics (STOK). Reader posts, not aibio.space reporting, and not investment advice.
Rules
Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
Say whether you hold the stock. Every post states long, short or no position.
No paid or sponsored posts. Do not post for anyone who pays or rewards you.
No buy or sell calls and no price targets.
No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
No personal details and no spam. No links at all for your first 7 days as a member.
Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.
Capital-markets timeline
Financings, listing notices, splits, legal actions and other investor events at Stoke Therapeutics, newest first. Each line links the filing it comes from.
Reported a change of independent auditor. SEC Form 8-K (Items 4.01,9.01). Source
Financings
Set up an at-the-market program to sell shares over time. SEC Form S-3ASR. Source
Financings
Set up an at-the-market program to sell shares over time. SEC Form S-3. Source
Stock chart
Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open NASDAQ:STOK on TradingView.
SEC filings and registration
SEC name
Stoke Therapeutics, Inc.
CIK
1623526
Industry (SIC)
Pharmaceutical Preparations (2834)
US tickers
STOK (Nasdaq)
State or country of incorporation
DE
Fiscal year ends
December 31
Filer category
Non-accelerated filer<br>Smaller reporting company
Business address
45 WIGGINS AVENUE, BEDFORD, MA, 01730
Phone
781-430-8200
Shares outstanding
64,526,242 as of 2026-07-30 (10-Q filed 2026-08-03)
Former names
ASOthera Pharmaceuticals, Inc.
Recent filings (8-K and 6-K are the company's own announcements)
Source: SEC EDGAR, retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices.
Listing details
Stoke Therapeutics, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker STOK, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.
Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.
Published and maintained by aibio.space. Not investment advice. How we work.
Who manages this pageThis page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio